SoylentNews is people
SoylentNews
Member of FDA’s expert panel resigns over Alzheimer’s therapy approval:
Following the Food and Drug Administration's polarizing authorization of the Alzheimer's therapy Aduhelm on Monday, a member of an agency advisory committee that recommended against the drug's approval has resigned.
Neurologist Joel Perlmutter of Washington University in St. Louis, a member of the FDA's expert panel for nervous system therapies, told STAT in an email that he had quit the committee on Monday "due to this ruling by the FDA without further discussion with our advisory committee."
The advisory committee, which convened in November, couldn't have been more openly skeptical of the drug, also known as aducanumab. Ten of the 11 panelists found that there was not enough evidence to show it could slow cognitive decline. The 11th voted "uncertain."
(Score: 2) by looorg on Friday June 11 2021, @08:59PM
I don't or wouldn't blame them. If I was in their shoes, had their resources and said affliction I would try anything to. There is probably no "cure" I wouldn't try if it came down to it.
But it doesn't change that the price-tag is ludicrous and insane. Or that the FDA have apparently approved a drug that nobody appears to believe in and it seems very doubtful that it will actually work. At best it appears to be a 56k dollar (per year) placebo. Perhaps their massive influx of cash will do something good and fuel further research, but it doesn't really change how f*cked this appears to be. If anything it might just have fed the executive coke and hooker party for a few more years.